Empagliflozin in Patients with Chronic Kidney Disease

• Published in: The New England journal of medicine Vol. 388; no. 2; pp. 117 - 127
• Main Authors: Herrington, William G, Staplin, Natalie, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Emberson, Jonathan R, Preiss, David, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K, Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P, Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R, Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J, Baigent, Colin, Haynes, Richard
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 12.01.2023
• Subjects: Albumin; Antidiabetics; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Cardiology; Cardiovascular Diseases - chemically induced; Chronic Kidney Disease; Clinical Medicine; Clinical Medicine General; Congestive heart failure; Creatinine; Creatinine - urine; Death; Design; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Disease Progression; End-stage renal disease; Endocrinology; Epidermal growth factor receptors; Glomerular Filtration Rate; Heart failure; Hemodialysis; Hospitalization; Humans; Kidney - physiopathology; Kidney diseases; Kidney transplants; Nephrology; Patient safety; Placebos; Prevention; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Statistical analysis; Values

The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. We enrolled patients with chronic kidney d...